Conventional DMARDs in axial spondyloarthritis: Wishful - Rather than rational - Thinking!

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 951-953

  Landewé, Robert B M ^a,b  

^a Amsterdam Rheumatology and Immunology Center   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR RECEPTOR;

AXIAL SPONDYLOARTHRITIS; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; FEASIBILITY STUDY; HUMAN; IMMUNOGENICITY; OBSERVATIONAL STUDY; POST HOC ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SPONDYLARTHRITIS; FEMALE; MALE; SPONDYLITIS, ANKYLOSING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; SULFASALAZINE;

EID: 84934889443     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206758     Document Type: Editorial

References (9)

1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
2. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
3. Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
4. de Vries MK, Wolbink GJ, Stapel SO, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007;66:133-4.
5. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009;68:1787-8.
6. Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014;53:213-22.
7. Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58:88-97.
8. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:531-5.
9. Lie E, Kristensen LE, Forsblad-d'Elia H, et al., for the ARTIS Study Group. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 2015;74:970-8.